stapokibart

Monoclonal antibody

Also known as CM310

Approvedregulatory verdict

Evidence outlook

Approved: Seasonal allergic rhinitis (SAR) (CN)

This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Reliable signal

Also in development:Asthma · Phase 2/3 · investigational in the USChronic Obstructive Pulmonary Disease · Phase 2/3 · investigational in the USPrurigo Nodularis · Phase 3 · investigational in the US · under NMPA review

Also approved (3)
CN
  • Seasonal allergic rhinitis (SAR)Outside this platform's coverage
  • Chronic rhinosinusitis with nasal polyps (CRSwNP)
  • Adult moderate-to-severe atopic dermatitis (Kangyueda)
Product first approved 2024allsci.com

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (9)
Atopic Dermatitis
NCT06495229 · Keymed Biosciences Co.Ltd
2024-08-02 – 2026-08-30 · Atopic Dermatitis
What this study did
NCT06956196 · Keymed Biosciences Co.Ltd
2025-05 – 2026-08 · Atopic Dermatitis
What this study did
Prurigo Nodularis
NCT06424470 · Keymed Biosciences Co.Ltd
2024-06-25 – 2026-02-11 · Prurigo Nodularis
What this study did
Other / comorbidity
NCT07210554 · Chengdu Kangnuoxing Biopharma,Inc.
2025-11-11 – 2028-05-08 · Bullous Pemphigoid (BP)
What this study did
NCT07678931 · Chengdu Kangnuoxing Biopharma,Inc.
2026-08-13 – 2026-12 · Seasonal Allergic Rhinitis (SAR)
What this study did
NCT05908032 · Keymed Biosciences Co.Ltd
2023-08-10 – 2023-12-04 · Allergic Rhinitis
What this study did
Phase 2/3 (2)
Asthma
NCT05761028 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2023-04-28 – 2032-05 · Moderate to Severe Asthma
What this study did
Chronic Obstructive Pulmonary Disease
NCT06547333 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2024-09-13 – 2032-10-31 · Chronic Obstructive Pulmonary Disease
What this study did
Phase 2 (16)
Asthma
NCT05186909 · Keymed Biosciences Co.Ltd
2022-01-12 – 2023-09-13 · Asthma
What this study did
Atopic Dermatitis
NCT06116565 · Keymed Biosciences Co.Ltd
2023-12-21 – 2025-11-26 · Atopic Dermatitis
What this study did
NCT05715320 · Keymed Biosciences Co.Ltd
2023-03-10 – 2024-07-18 · Atopic Dermatitis
What this study did
NCT05579925 · Keymed Biosciences Co.Ltd
2022-10-07 – 2023-07-28 · Atopic Dermatitis
What this study did
NCT04893707 · Keymed Biosciences Co.Ltd
2021-06-07 – 2023-02-03 · Moderate-to-severe Atopic Dermatitis
What this study did
NCT04805411 · Keymed Biosciences Co.Ltd
2021-02-24 – 2021-11-08 · Moderate-to-severe Atopic Dermatitis
What this study did
Other / comorbidity
NCT07791615 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-12 – 2029-06 · Lymphoma, NK T-Cell Lymphoma
What this study did
NCT07617324 · Chengdu Kangnuoxing Biopharma,Inc.
2026-06 – 2027-02 · Seasonal Allergic Rhinitis (SAR)
What this study did
NCT06300203 · Beijing Tongren Hospital
2024-03-18 – 2026-06-30 · Seasonal Allergic Rhinitis
What this study did
NCT06525597 · Keymed Biosciences Co.Ltd
2024-09-30 – 2025-10-30 · Allergic Rhinitis
What this study did
NCT06171074 · Keymed Biosciences Co.Ltd
2024-03-30 – 2025-03-30 · Seasonal Allergic Rhinitis
What this study did
NCT05452343 · Keymed Biosciences Co.Ltd
2022-08-30 – 2024-03-01 · Chronic Pruritus of Unknown Origin
What this study did
NCT05131464 · Keymed Biosciences Co.Ltd
2021-11-30 – 2024-01-31 · Chronic Rhinosinusitis With Nasal Polyps
What this study did
NCT05908721 · Keymed Biosciences Co.Ltd
2023-08-23 – 2023-12-10 · Allergic Rhinitis
What this study did
NCT05470647 · Beijing Tongren Hospital
2022-08-17 – 2022-12-28 · Allergic Rhinitis
What this study did
NCT04805398 · Keymed Biosciences Co.Ltd
2021-04-06 – 2022-03-18 · Chronic Rhinosinusitis (Diagnosis), Nasal Polyps
What this study did
Phase 1/2 (2)
Atopic Dermatitis
NCT06162507 · Keymed Biosciences Co.Ltd
2023-12-22 – 2024-07-04 · Atopic Dermatitis
What this study did
NCT04893941 · Keymed Biosciences Co.Ltd
2020-07-21 – 2021-01-22 · Moderate-to-severe Atopic Dermatitis
What this study did
Phase 1 (4)
Other / comorbidity
NCT07040072 · Beijing Tongren Hospital
2025-10-09 – 2028-06 · HNSCC
What this study did
NCT06171048 · Keymed Biosciences Co.Ltd
2024-04-30 – 2025-04-30 · Healthy
What this study did
NCT05702450 · Keymed Biosciences Co.Ltd
2023-03-22 – 2023-07-26 · Healthy
What this study did
NCT06161090 · Keymed Biosciences Co.Ltd
2019-09-03 – 2020-01-13 · Healthy
What this study did
Phase 4 (1)
Other / comorbidity
NCT06801353 · Beijing Tongren Hospital
2025-02-01 – 2026-07-01 · Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Biological Therapy, Biomarkers
What this study did
Early phase / not applicable (5)
Other / comorbidity
NCT07616609 · Beijing Tongren Hospital
2026-06-01 – 2028-12-31 · Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
What this study did
NCT07240376 · Huazhong University of Science and Technology
2025-11-25 – 2027-02-28 · Non-Allergic Rhinitis With Eosinophilia Syndrome
What this study did
NCT07073664 · China-Japan Union Hospital
2025-04-21 – 2026-12-31 · Chronic Sinusitis
What this study did
NCT07143864 · First Affiliated Hospital of Chongqing Medical University
2025-09-15 – 2026-12-31 · Primary Cutaneous Amyloidosis
What this study did
NCT05728684 · Beijing Friendship Hospital
2023-02-20 – 2024-04-23 · IgG4 Related Disease
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Other / comorbidity
NCT05436275 · Keymed Biosciences Co.Ltd
2022-08-09 – 2024-06-25 · Chronic Rhinosinusitis With Nasal Polyposis
What this study did

Competitive landscape

This mechanism is crowded: 10 other tracked programmes target it, 1 of them ahead of this one.

This drug's own stage for Atopic Dermatitis: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Stapokibart: this drugPhase 3Monoclonal antibodyIL-4R-alphaReliable signal
NCT06277765: EASI-75 at week 18: 73.9% (88/119) stapokibart vs 43% (26/60) placebo; difference 30.5 percentage points (95% CI 15.3-44.3; P<0.001)
NCT05265923: EASI-75 response at week 16: 66.9% stapokibart vs 25.8% placebo (significantly higher)
Abrocitinib (Cibinqo)ApprovedSmall moleculeJAK1Reliable signal
NCT04345367: Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2 (Week 2): Abrocitinib 200 mg QD 48.2% (95% CI 43 to 53.4) vs Dupilumab 300 mg Q2W 25.5% (95% CI 21.1 to 30)
NCT03349060: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to 2 Points Improvement From Baseline at Week 12 (Baseline, Week 12): PF-04965842 100 mg 23.7% | PF-04965842 200 mg 43.8% vs Placebo 7.9%
Crisaborole (Eucrisa)ApprovedSmall moleculePDE4Reliable signal
NCT02118766: Percentage of Participants Who Achieved Treatment Success Based on Investigator's Static Global Assessment (ISGA) at Day 29 (Day 29): AN2728 Topical Ointment, 2 Percent 32.8% vs AN2728 Topical Ointment, Vehicle 25.4%
NCT02118792: Percentage of Participants Who Achieved Success in Investigator's Static Global Assessment (ISGA) Score at Day 29 (Day 29): AN2728 Ointment, 2 Percent (%) 31.4% vs AN2728 Ointment, Vehicle 18%
Difamilast (Moizerto / Adquey)ApprovedSmall moleculePDE4Partial signal
NCT03908970: Responder Rate of Investigator's Global Assesment(IGA) of Disease Severity (At Week 4): 1% OPA-15406 38.46% (95% CI 31.36 to 45.95) vs Placebo 12.64% (95% CI 8.18 to 18.36)
NCT03911401: IGA success (score 0 or 1 with at least a 2-grade improvement) at week 4: difamilast 0.3% 44.6% and 1% 47.1% vs vehicle 18.1%; p<0.001 for each dose vs vehicle. n=83, 85, 83 (Saeki 2022, Br J Dermatol).
Dupilumab (Dupixent)ApprovedMonoclonal antibodyIL-4R-alphaWeak signal
NCT04417894: Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16 (At week 16): Dupilumab Q2W 40.3% vs Matching Placebo 16.7%
NCT03345914: Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16 (Week 16): Dupilumab 300 mg Q4W + TCS 32.8% | Dupilumab 100 mg or 200 mg Q2W + TCS 29.5% vs Placebo + TCS 11.4%
Lebrikizumab (Ebglyss)ApprovedMonoclonal antibodyIL-13Reliable signal
NCT04178967: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 (Baseline to Week 16): Lebrikizumab Q2W 33.2% (95% CI 27.5 to 38.9) vs Placebo 10.8% (95% CI 5.7 to 15.9)
NCT04146363: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 (Baseline to Week 16): Lebrikizumab Q2W 43.1% (95% CI 37.1 to 49) vs Placebo 12.7% (95% CI 7 to 18.5)
Nemolizumab (Nemluvio)ApprovedMonoclonal antibodyIL-31 receptor AReliable signal
NCT03989349: Percentage of Participants With Investigator's Global Assessment (IGA) Success at Week 16: Intent-To-Treat (ITT) Population (Week 16): Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg 37.7% vs Initial Treatment Period (Baseline - Week 16 Predose): Placebo 26%
NCT03985943: Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT) Population (Week 16): Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg 35.6% vs Initial Treatment Period (Baseline - Week 16 Predose): Placebo 24.6%
Roflumilast (Zoryve)ApprovedSmall moleculePDE4Reliable signal
NCT06631170: Primary endpoint, Week 4 IGA (vIGA-AD) treatment-success rate: 31.9% with 0.15% roflumilast cream vs 6.7% with vehicle (P<0.0001)
NCT04773600: Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4 (Week 4): Roflumilast Cream 0.15% 28.9% vs Vehicle Cream 12%
Ruxolitinib (Opzelura)ApprovedSmall moleculeJAK1/2Reliable signal
NCT03745638: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 (Baseline to Week 8): VC Period: Ruxolitinib 0.75% Cream BID 50% (95% CI 43.7 to 56.3) | VC Period: Ruxolitinib 1.5% Cream BID 53.8% (95% CI 47.4 to 60) vs VC Period: Vehicle Cream BID 15.1% (95% CI 9.3 to 22.5)
NCT03745651: VC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 (Baseline to Week 8): VC Period: Ruxolitinib 0.75% Cream BID 39% (95% CI 32.6 to 45.6) | VC Period: Ruxolitinib 1.5% Cream BID 51.3% (95% CI 44.6 to 58) vs VC Period: Vehicle Cream BID 7.6% (95% CI 3.5 to 14)
TapinarofApprovedSmall moleculeAryl hydrocarbon receptor, Aryl Hydrocarbon Receptor AgonistReliable signal
NCT05014568: Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation. (Baseline to Week 8): Tapinarof Cream 45.4% vs Vehicle Cream 13.9%
NCT05032859: Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation. (Baseline to Week 8): Tapinarof Cream 46.4% vs Vehicle Cream 18%
Tralokinumab (Adbry)ApprovedMonoclonal antibodyIL-13Reliable signal
NCT05958407: Percentage of Participants With IGA-AHE Score of 0 (Clear) or 1 (Almost Clear) (At Week 16): Tralokinumab 40% (95% CI 31.3 to 49.4) vs Placebo 10.6% (95% CI 5 to 20.9)
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03607422: EASI-75 response at week 16 (Measure Up 2): 60.1% (upadacitinib 15 mg) vs 72.9% (upadacitinib 30 mg) vs 13.3% (placebo).
NCT03569293: EASI-75 at week 16 (Measure Up 1): 70% (196/281) upadacitinib 15mg, 80% (227/285) upadacitinib 30mg, vs 16% (46/281) placebo; adjusted difference vs placebo 53.3% [46.4-60.2] and 63.4% [57.1-69.8] respectively, both p<0.0001
ADSTEMPhase 3Cell therapyautologous adipose-derived mesenchymal stem cell (AD-MSC) therapynot yet gradedNo reviewed efficacy summary in this indication
AsivatrepPhase 3Small moleculeTRPV1Reliable signal
NCT02965118: IGA success (score 0 or 1) at week 8: 36.0% asivatrep vs 12.8% vehicle (P<.001)
Baricitinib (Olumiant)Phase 3Small moleculeJAK, JAK1/2Reliable signal
NCT03334422: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2mg and 4mg Baricitinib) (16 Weeks): 2mg Baricitinib 10.6% | 4mg Baricitinib 13.8% vs Placebo 4.5%
NCT03334396: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2 mg, or 4 mg Baricitinib) (16 Weeks): 2 mg Baricitinib 11.4% | 4 mg Baricitinib 16.8% vs Placebo 4.8%
GS101Phase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
Jaktinib (Zepuping)Phase 3Small moleculeJAK1/2/3Partial signalNo reviewed efficacy summary in this indication
LW402Phase 3Small moleculeJAK1Partial signalNo reviewed efficacy summary in this indication
ManfidokimabPhase 3Monoclonal antibodyIL-4R-alphaPartial signalNo reviewed efficacy summary in this indication
PumecitinibPhase 3Small moleculeJAK1/2not yet gradedNo reviewed efficacy summary in this indication
QL2108Phase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
QLM3003Phase 3Small moleculeJAKPartial signalNo reviewed efficacy summary in this indication
RademikibartPhase 3Monoclonal antibodyIL-4R-alphaPartial signal
NCT05017480: vIGA 0/1 with a reduction of 2 points or more at week 16: rademikibart 300 mg Q2W 29.0% vs placebo 5.9%, P<0.001 (SEASIDE CHINA, Br J Dermatol 2026).
RezpegaldesleukinPhase 3Protein / enzyme therapeuticIL-2 mutein (Treg-selective)not yet gradedNo reviewed efficacy summary in this indication
SHR-1819Phase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
Soficitinib (ICP-332)Phase 3Small moleculeTYK2/JAK1not yet gradedNo reviewed efficacy summary in this indication
SSGJ-611Phase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
TelikibartPhase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
TilrekimigPhase 3Multispecific antibodyIL-4/IL-13/TSLPnot yet gradedNo reviewed efficacy summary in this indication
VC005Phase 3Small moleculeJAK1, JAK1not yet gradedNo reviewed efficacy summary in this indication
ZemprocitinibPhase 3Small moleculeJAK1Reliable signal
NCT06277245: EASI-75 at Week 16: +38.1 percentage points (12 mg) and +46.4 percentage points (24 mg) vs placebo (p<0.0001); IGA 0/1 response: +30.3 percentage points (12 mg) and +31.0 percentage points (24 mg) vs placebo (p<0.0001)
AfimkibartPhase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
AK139Phase 2Multispecific antibodyIL-4 receptor alpha / ST2not yet gradedNo reviewed efficacy summary in this indication
BarzolvolimabPhase 2Monoclonal antibodyKITnot yet gradedNo reviewed efficacy summary in this indication
BempikibartPhase 2Monoclonal antibodyIL-7 receptor alphanot yet gradedNo reviewed efficacy summary in this indication
BFB759Phase 2Monoclonal antibodyIL-1RAPnot yet gradedNo reviewed efficacy summary in this indication
BosakitugPhase 2Monoclonal antibodyTSLPWeak signal
NCT05932654: Proportion of Patients Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 26 (Week 26): 300 mg 94.1% (95% CI 71.3 to 99.9)
CamoteskimabPhase 2Monoclonal antibodyIL-18Partial signalNo reviewed efficacy summary in this indication
CM512Phase 2Multispecific antibodyTSLP + IL-13Weak signalFeatured results are safety only in this race
CMS-D001Phase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
ENV-294Phase 2Small molecule—Weak signalFeatured results are safety only in this race
EVO101Phase 2Small moleculeIRAK4Partial signal
NCT05579899: Percent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8 (8 weeks): EVO101 Cream -43.5% (Standard Deviation 60.85) vs Vehicle Cream -62% (Standard Deviation 38.78) missed
EVO301Phase 2Protein / enzyme therapeuticIL-18Partial signal
NCT06723405: Placebo-adjusted improvement in EASI at Week 12: 33% (95% CI -50, -17; p<0.01)
FB825Phase 2Monoclonal antibodyCεmX domain of membrane-bound IgE (mIgE)Weak signalNo reviewed efficacy summary in this indication
FelcorekibartPhase 2Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
GalvokimigPhase 2Multispecific antibodyIL-13, IL-17A, IL-17FPartial signalFeatured results are safety only in this race
GHZ339Phase 2Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication
GIA632Phase 2Monoclonal antibodyIL-15not yet gradedNo reviewed efficacy summary in this indication
HSK44459Phase 2Small moleculePDE4Bnot yet gradedNo reviewed efficacy summary in this indication
HY209gelPhase 2Small moleculeGPCR19 / GPBAR1 (TGR5, bile acid receptor)Partial signalFeatured results are safety only in this race
IN-115314Phase 2Small moleculeJAK1not yet gradedNo reviewed efficacy summary in this indication
JNJ-95597528Phase 2Multispecific antibodyTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
JYP0061Phase 2Small moleculeJAK1not yet gradedNo reviewed efficacy summary in this indication
KT-621Phase 2Small moleculeSTAT6Weak signalFeatured results are safety only in this race
LepzacitinibPhase 2Small moleculeJAK1/JAK3not yet gradedNo reviewed efficacy summary in this indication
LNK01004Phase 2Small moleculePan-JAKPartial signalFeatured results are safety only in this race
LT-002-158Phase 2Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
LunsekimigPhase 2Antibody-derived scaffoldTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
LutikizumabPhase 2Multispecific antibodyIL-1α/IL-1β (dual)not yet gradedNo reviewed efficacy summary in this indication
ModzatinibPhase 2Small moleculeITK and JAK3not yet gradedNo reviewed efficacy summary in this indication
MosedipimodPhase 2Small moleculeNF-kB / CCL26 pathwaynot yet gradedNo reviewed efficacy summary in this indication
Nitrosomonas Eutropha (B244)Phase 2Microbiome therapeuticlive biotherapeutic (topical ammonia-oxidizing bacterium, AOBiome/B244)Reliable signal
NCT04490109: Mean Change in Worst Itch Numeric Rating Scale (WI-NRS) (Baseline to Day 28): B244 O.D. 5.0 -2.8 score on a scale (Standard Error 0.184) | B244 O.D. 20.0 -2.8 score on a scale (Standard Error 0.184) vs Vehicle -2.1 score on a scale (Standard Error 0.18)
OlevaprubartPhase 2Monoclonal antibodyOX40Weak signalFeatured results are safety only in this race
OmpekimigPhase 2Multispecific antibodyIL-4, IL-13, IL-33Partial signal
NCT05995964: Stage 1, high-dose ompekimig vs placebo: met the primary endpoint (EASI-75 at week 16); no ompekimig figures were given (2026-03-09).
OpSCFPhase 2Monoclonal antibodyStem cell factor (SCF / KIT ligand)Partial signal
NCT06101823: Percent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 16 (Baseline, Week 16): OpSCF 600 mg -71.476 percent change (Standard Error 8.6876) | OpSCF Matching-Placebo -50.992 percent change (Standard Error 8.8073)
OrismilastPhase 2Small moleculePDE4B/DPartial signal
NCT05469464: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16 (Baseline and Week 16): Orismilast Modified Release Tablets 20 mg BID -55.1% (Standard Error 4.89) | Orismilast Modified Release Tablets 30 mg BID -52.2% (Standard Error 5.39) | Orismilast Modified Release Tablets 40 mg BID -61.4% (Standard Error 5.02) vs Placebo Tablets BID -50.4% (Standard Error 4.98) missed
NCT02496546: In adults with mild to moderate atopic dermatitis treated twice daily for 3 weeks, total sign score at end of treatment was 5.2 (least squares mean 5.1) with orismilast cream 20 mg/g versus 6.2 (LS mean 6.3) with vehicle, a statistically significant difference (P = .014).
PF-08049820Phase 2Small moleculeSTAT6not yet gradedNo reviewed efficacy summary in this indication
PUR 0110Phase 2——not yet gradedNo reviewed efficacy summary in this indication
QLS12010Phase 2Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
XKH001Phase 2Monoclonal antibodyIL-25not yet gradedNo reviewed efficacy summary in this indication
CKD-706Phase 1Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
ItepekimabDiscontinuedMonoclonal antibodyIL-33not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 71 furthest-along competitors are listed; 41 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow stapokibart to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
December 2026 (4)
Phase 3Seasonal Allergic Rhinitis (SAR)Recruiting
Est. primary completion 2026-12 · NCT07678931 · CT.gov ↗
What to watch
Early phase / not applicableChronic SinusitisEnrolling by invitation
Est. primary completion 2026-12-31 · NCT07073664 · CT.gov ↗
What to watch
Early phase / not applicablePrimary Cutaneous AmyloidosisNot yet recruiting
Est. primary completion 2026-12-31 · NCT07143864 · CT.gov ↗
What to watch
Early phase / not applicableNon-Allergic Rhinitis With Eosinophilia SyndromeNot yet recruiting
Est. primary completion 2026-12-31 · NCT07240376 · CT.gov ↗
What to watch
2027 (2)
February 2027 (1)
Phase 3Atopic DermatitisNot yet recruiting
Est. primary completion 2027-02 · NCT07106372 · CT.gov ↗
What to watch
June 2027 (1)
Phase 1HNSCCRecruiting
Est. primary completion 2027-06 · NCT07040072 · CT.gov ↗
What to watch
2028 (3)
March 2028 (1)
Phase 3Bullous Pemphigoid (BP)Not yet recruiting
Est. primary completion 2028-03-27 · NCT07210554 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2Lymphoma, NK T-Cell LymphomaNot yet recruiting
Est. primary completion 2028-06 · NCT07791615 · CT.gov ↗
What to watch
December 2028 (1)
Early phase / not applicableChronic Rhinosinusitis With Nasal Polyps (CRSwNP)Not yet recruiting
Est. primary completion 2028-12-31 · NCT07616609 · CT.gov ↗
What to watch
2032 (2)
April 2032 (1)
Phase 2/3Chronic Obstructive Pulmonary DiseaseNot yet recruiting
Est. primary completion 2032-04-29 · NCT06547333 · CT.gov ↗
What to watch
May 2032 (1)
Phase 2/3AsthmaRecruiting
Est. primary completion 2032-05 · NCT05761028 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

March 2026Filing acceptedNMPA accepts stapokibart application in prurigo nodularis
CN, NMPA · Keymed Biosciences · Source ↗
January 2026Filing acceptedNMPA accepts stapokibart application in adolescent AD
CN, NMPA · Keymed Biosciences · Source ↗
28 April 2024Topline resultPhase III PHECDA (NCT05908032) in seasonal allergic rhinitis met its primary endpoint
Keymed Biosciences Inc. · Source ↗